Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Instituto de Investigación Biomédica de Málaga (IBIMA), Faculty of Medicine, University of Málaga, Málaga, Spain.
Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Front Endocrinol (Lausanne). 2022 Apr 14;13:838887. doi: 10.3389/fendo.2022.838887. eCollection 2022.
Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome.
A型胰岛素抵抗（IR）综合征是一种罕见的遗传性疾病，影响胰岛素受体（INSR）基因，其特征为严重的胰岛素抵抗而无肥胖。患有这种疾病的患者最终会发展为糖尿病，对胰岛素增敏剂（如二甲双胍和噻唑烷二酮）和大剂量胰岛素的反应存在差异。我们首次报告了在 A 型 IR 综合征的背景下，使用胰高血糖素样肽-1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂联合治疗糖尿病的结果。
